Hippocampal subfield transcriptome analysis in schizophrenia psychosis

Area of Science:

• Neuroscience
• Molecular Biology
• Psychiatry

Background:

• Schizophrenia (SZ) is associated with functional and molecular alterations in hippocampal subfields, linked to hippocampal excitability.
• Previous research established a connection between SZ psychosis and hippocampal changes, necessitating a deeper molecular investigation.

Purpose of the Study:

• To elucidate subfield-relevant molecular changes in the hippocampus (DG, CA3, CA1) in individuals with schizophrenia (SZ) psychosis using RNA-sequencing.
• To examine the impact of antipsychotic medication on gene expression within these hippocampal subfields in SZ patients.
• To identify unique molecular profiles specific to each hippocampal subfield in SZ and differentiate disease effects from medication effects.

Main Methods:

• RNA-sequencing (RNA-seq) was employed to assess global transcriptome changes.
• Postmortem hippocampal subfields (DG, CA3, CA1) from individuals with SZ psychosis and controls were analyzed.
• Gene expression patterns were compared between SZ patients on and off antipsychotic medication.

Main Results:

• Unique subfield-specific molecular profiles were identified in SZ postmortem samples compared to controls.
• Specific molecular mechanisms implicated include astrocytes in the DG, immune mechanisms in the CA3, and synaptic scaling in the CA1.
• Antipsychotic medication demonstrated a distinct pattern of subfield-specific effects on gene expression with minimal overlap with SZ disease effects.

Conclusions:

• The findings confirm and extend the existing model of SZ, highlighting distinct molecular profiles in hippocampal subfields.
• The observed subfield-specific changes may explain the limited efficacy of conventional antipsychotic medications on SZ symptomatology.
• Identified molecular profiles in DG, CA3, and CA1 offer potential targets for future hippocampal-based therapeutic strategies in SZ.